Related Experiment Videos

Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5

Zhi-Kai Zhang1, Kelvin P Davies, Jeffrey Allen

  • 1Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Insights

INI1/hSNF5, a tumor suppressor, halts AT/RT cell growth by repressing cyclin D1 via HDAC recruitment. Restoring INI1/hSNF5 expression in AT/RT cells induces cell cycle arrest and flat cell formation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • INI1/hSNF5 is a tumor suppressor crucial for pediatric atypical teratoid and malignant rhabdoid tumors (AT/RT).
  • Understanding INI1/hSNF5's tumor suppressor mechanisms is vital for AT/RT treatment strategies.

Purpose of the Study:

  • To elucidate the molecular mechanisms of INI1/hSNF5's tumor suppressor function in AT/RT.
  • To investigate the role of INI1/hSNF5 in cell cycle regulation and gene expression.

Main Methods:

  • Reintroduction of INI1/hSNF5 into AT/RT-derived cell lines (MON).
  • Analysis of cell cycle progression (G(0)-G(1) arrest) and cell morphology.
  • Chromatin immunoprecipitation (ChIP) to assess INI1/hSNF5 and HDAC1 recruitment to the cyclin D1 promoter.
  • Histone deacetylase (HDAC) activity assays and cyclin D1 expression analysis.

Main Results:

  • INI1/hSNF5 reintroduction induced G(0)-G(1) cell cycle arrest and flat cell formation in MON cells.
  • INI1/hSNF5 repressed cyclin D1 gene transcription in a manner dependent on HDAC activity.
  • INI1/hSNF5 directly recruited HDAC1 to the cyclin D1 promoter, leading to histone deacetylation and gene repression.
  • Overexpression of cyclin D1 in AT/RT tumors was observed, and its reintroduction reversed INI1-mediated effects.

Conclusions:

  • INI1/hSNF5 exerts tumor suppressor functions by recruiting HDAC activity to the cyclin D1 promoter, causing repression and G(0)-G(1) arrest.
  • Cyclin D1 repression is a key mechanism underlying INI1/hSNF5's anti-tumorigenic effects in AT/RT.
  • Targeting cyclin D1 expression may represent a therapeutic strategy for AT/RT.

Related Concept Videos